Sandoz Pushes Further Into High-Barrier Generics With $1.5B Acquisition of Fougera
This article was originally published in The Pink Sheet Daily
Executive Summary
Sandoz is acquiring the U.S. generics dermatology business Fougera, which formerly belonged to Nycomed, for $1.5 billion in cash, giving it entry into a highly profitable niche market.